Abstract：
In recent years, there have been a number of studies where hesperidin was administered to modify arterial blood pressure, but the conclusions of each study are contradictory. In order to investigate the effect of hesperidin on blood pressure, we searched the CNKI, Wanfang Database, the VIP database, Sinomed database, Pubmed, Embase and The Cochrane Library databases, and searched the literature on hesperidin and blood pressure published in Chinese and English journals, mainly focusing on patients\' systolic blood pressure and diastolic blood pressure. The search time frame was from the inception of the databases until December 2023. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the overall quality and used Cohen\'s kappa coefficient (κ) to measure agreement. We did preliminary screening of the retrieved literature through Notexpress, 14 articles with a total of 656 patients were included. Cochrance data conversion tool was used for data conversion, and RevMan 5.3 was used for meta-analysis, and finally Stata was used to make the Egger\'s test for the included study. The results of total population blood pressure showed that hesperidin had no antihypertensive effect on the population, but the conclusions changed when the population was divided into groups. The results of different populations showed that hesperidin had no effect on systolic blood pressure (weighted mean difference [WMD] = -0.50, 95% CI: -3.25 ~ 2.26, Z = 0.35, p = 0.72) and diastolic blood pressure (WMD = -0.51, 95% CI: -2.53 ~ 1.51, Z = 0.50, p = 0.62) in healthy individuals. However, hesperidin reduced systolic blood pressure in patients with type 2 diabetes (WMD = -4.32, 95% CI: - 7.77 ~ - 0.87, Z = 2.45, p = 0.01), and had a tendency to reduce diastolic blood pressure in diabetic patients (WMD = -3.72, 95% CI: -7.63 ~ 0.18, Z = 1.87, p = 0.06). The results in patients with type 2 diabetes needed to be further supported by future research focusing on individuals with diabetes.
摘要：
近年来,有许多研究表明服用橙皮苷来改善动脉血压，但是每个研究的结论都是矛盾的。为了研究橙皮苷对血压的影响,我们搜索了CNKI，万方数据库,VIP数据库,Sinomed数据库,Pubmed,Embase和Cochrane图书馆数据库，并检索了中英文期刊上发表的关于橙皮苷和血压的文献，主要关注患者的收缩压和舒张压。搜索时间范围是从数据库开始到2023年12月。建议评估的分级，发展,使用评估（GRADE）方法评估总体质量，并使用科恩的卡帕系数（κ）来衡量一致性。我们通过Notexpress对检索到的文献进行了初步筛选，共纳入14篇文献，共656例患者。Cochrance数据转换工具用于数据转换，RevMan5.3用于荟萃分析，最后，Stata被用来对纳入研究的Egger进行测试。总人群血压检测结果显示橙皮苷对人群无降压作用,但是当人口被分成几组时，结论就改变了。不同人群的结果显示,橙皮苷对健康个体收缩压(加权平均差值[WMD]=-0.50,95%CI:-3.25~2.26,Z=0.35,p=0.72)和舒张压(WMD=-0.51,95%CI:-2.53~1.51,Z=0.50,p=0.62)无影响。然而,橙皮苷降低2型糖尿病患者收缩压(WMD=-4.32,95%CI:-7.77~-0.87,Z=2.45,p=0.01),并有降低糖尿病患者舒张压的趋势(WMD=-3.72,95%CI:-7.63~0.18,Z=1.87,p=0.06)。2型糖尿病患者的结果需要未来针对糖尿病患者的研究进一步支持。
